Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Synthesis and anti-staphylococcal activity of novel bacterial topoisomerase inhibitors with a 5-amino-1,3-dioxane linker moiety.

Li L, Okumu A, Dellos-Nolan S, Li Z, Karmahapatra S, English A, Yalowich JC, Wozniak DJ, Mitton-Fry MJ.

Bioorg Med Chem Lett. 2018 Aug 1;28(14):2477-2480. doi: 10.1016/j.bmcl.2018.06.003. Epub 2018 Jun 1.

PMID:
29871847
2.

Synthesis and antiproliferative activity of derivatives of the phyllanthusmin class of arylnaphthalene lignan lactones.

Woodard JL, Huntsman AC, Patel PA, Chai HB, Kanagasabai R, Karmahapatra S, Young AN, Ren Y, Cole MS, Herrera D, Yalowich JC, Kinghorn AD, Burdette JE, Fuchs JR.

Bioorg Med Chem. 2018 May 15;26(9):2354-2364. doi: 10.1016/j.bmc.2018.03.033. Epub 2018 Mar 23.

PMID:
29656990
3.

The Novel C-terminal Truncated 90-kDa Isoform of Topoisomerase IIα (TOP2α/90) Is a Determinant of Etoposide Resistance in K562 Leukemia Cells via Heterodimerization with the TOP2α/170 Isoform.

Kanagasabai R, Karmahapatra S, Kientz CA, Yu Y, Hernandez VA, Kania EE, Yalowich JC, Elton TS.

Mol Pharmacol. 2018 May;93(5):515-525. doi: 10.1124/mol.117.111567. Epub 2018 Mar 7.

PMID:
29514855
4.

Capsicodendrin from Cinnamosma fragrans Exhibits Antiproliferative and Cytotoxic Activity in Human Leukemia Cells: Modulation by Glutathione.

Karmahapatra S, Kientz C, Shetty S, Yalowich JC, Rakotondraibe LH.

J Nat Prod. 2018 Mar 23;81(3):625-629. doi: 10.1021/acs.jnatprod.7b00887. Epub 2018 Feb 6.

PMID:
29406734
5.

Alternative RNA Processing of Topoisomerase IIα in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.

Kanagasabai R, Serdar L, Karmahapatra S, Kientz CA, Ellis J, Ritke MK, Elton TS, Yalowich JC.

J Pharmacol Exp Ther. 2017 Jan;360(1):152-163. Epub 2016 Nov 10.

6.

Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.

Hasinoff BB, Wu X, Patel D, Kanagasabai R, Karmahapatra S, Yalowich JC.

J Pharmacol Exp Ther. 2016 Feb;356(2):397-409. doi: 10.1124/jpet.115.228650. Epub 2015 Dec 11.

7.

TRIM72 modulates caveolar endocytosis in repair of lung cells.

Nagre N, Wang S, Kellett T, Kanagasabai R, Deng J, Nishi M, Shilo K, Oeckler RA, Yalowich JC, Takeshima H, Christman J, Hubmayr RD, Zhao X.

Am J Physiol Lung Cell Mol Physiol. 2016 Mar 1;310(5):L452-64. doi: 10.1152/ajplung.00089.2015. Epub 2015 Dec 4.

8.

Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.

Yadav AA, Chee GL, Wu X, Patel D, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2015 Jul 1;23(13):3542-51. doi: 10.1016/j.bmc.2015.04.022. Epub 2015 Apr 16.

9.

Cytotoxic and natural killer cell stimulatory constituents of Phyllanthus songboiensis.

Ren Y, Yuan C, Deng Y, Kanagasabai R, Ninh TN, Tu VT, Chai HB, Soejarto DD, Fuchs JR, Yalowich JC, Yu J, Kinghorn AD.

Phytochemistry. 2015 Mar;111:132-40. doi: 10.1016/j.phytochem.2014.12.014. Epub 2015 Jan 14.

10.

Cellular mechanisms of the cytotoxicity of the anticancer drug elesclomol and its complex with Cu(II).

Hasinoff BB, Wu X, Yadav AA, Patel D, Zhang H, Wang DS, Chen ZS, Yalowich JC.

Biochem Pharmacol. 2015 Feb 1;93(3):266-76. doi: 10.1016/j.bcp.2014.12.008. Epub 2014 Dec 27.

PMID:
25550273
11.

Experimental procedures to identify and validate specific mRNA targets of miRNAs.

Elton TS, Yalowich JC.

EXCLI J. 2015 Jul 2;14:758-90. doi: 10.17179/excli2015-319. eCollection 2015. Review.

12.

Structure-based design, synthesis and biological testing of etoposide analog epipodophyllotoxin-N-mustard hybrid compounds designed to covalently bind to topoisomerase II and DNA.

Yadav AA, Wu X, Patel D, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2014 Nov 1;22(21):5935-49. doi: 10.1016/j.bmc.2014.09.014. Epub 2014 Sep 16.

13.

Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.

Ren Y, Lantvit DD, Deng Y, Kanagasabai R, Gallucci JC, Ninh TN, Chai HB, Soejarto DD, Fuchs JR, Yalowich JC, Yu J, Swanson SM, Kinghorn AD.

J Nat Prod. 2014 Jun 27;77(6):1494-504. doi: 10.1021/np5002785. Epub 2014 Jun 12.

14.

The anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.

Hasinoff BB, Wu X, Nitiss JL, Kanagasabai R, Yalowich JC.

Biochem Pharmacol. 2012 Dec 15;84(12):1617-26. doi: 10.1016/j.bcp.2012.09.023. Epub 2012 Oct 5.

15.

The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase IIα.

Yalowich JC, Wu X, Zhang R, Kanagasabai R, Hornbaker M, Hasinoff BB.

Biochem Pharmacol. 2012 Jul 1;84(1):52-8. doi: 10.1016/j.bcp.2012.03.021. Epub 2012 Apr 4.

16.

Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.

Zhang R, Wu X, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2011 Dec 1;19(23):7023-32. doi: 10.1016/j.bmc.2011.10.012. Epub 2011 Oct 14.

17.

Cadmium is a catalytic inhibitor of DNA topoisomerase II.

Wu X, Yalowich JC, Hasinoff BB.

J Inorg Biochem. 2011 Jun;105(6):833-8. doi: 10.1016/j.jinorgbio.2011.02.007. Epub 2011 Feb 26.

18.

Myeloperoxidase-dependent oxidation of etoposide in human myeloid progenitor CD34+ cells.

Vlasova II, Feng WH, Goff JP, Giorgianni A, Do D, Gollin SM, Lewis DW, Kagan VE, Yalowich JC.

Mol Pharmacol. 2011 Mar;79(3):479-87. doi: 10.1124/mol.110.068718. Epub 2010 Nov 19.

19.

Toxicity issues in cancer drug development.

Gewirtz DA, Bristol ML, Yalowich JC.

Curr Opin Investig Drugs. 2010 Jun;11(6):612-4.

PMID:
20496255
20.

Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.

Zhang R, Wu X, Guziec LJ, Guziec FS, Chee GL, Yalowich JC, Hasinoff BB.

Bioorg Med Chem. 2010 Jun 1;18(11):3974-84. doi: 10.1016/j.bmc.2010.04.028. Epub 2010 Apr 18.

21.

The mismatch repair system modulates curcumin sensitivity through induction of DNA strand breaks and activation of G2-M checkpoint.

Jiang Z, Jin S, Yalowich JC, Brown KD, Rajasekaran B.

Mol Cancer Ther. 2010 Mar;9(3):558-68. doi: 10.1158/1535-7163.MCT-09-0627. Epub 2010 Feb 9.

22.

A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.

Chee GL, Yalowich JC, Bodner A, Wu X, Hasinoff BB.

Bioorg Med Chem. 2010 Jan 15;18(2):830-8. doi: 10.1016/j.bmc.2009.11.048. Epub 2009 Nov 27.

23.

The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.

Hasinoff BB, Zhang R, Wu X, Guziec LJ, Guziec FS Jr, Marshall K, Yalowich JC.

Bioorg Med Chem. 2009 Jul 1;17(13):4575-82. doi: 10.1016/j.bmc.2009.04.072. Epub 2009 May 6.

PMID:
19457675
24.

The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.

Hasinoff BB, Liang H, Wu X, Guziec LJ, Guziec FS Jr, Marshall K, Yalowich JC.

Bioorg Med Chem. 2008 Apr 1;16(7):3959-68. doi: 10.1016/j.bmc.2008.01.033. Epub 2008 Jan 26.

25.

Thiol-modulated mechanisms of the cytotoxicity of thimerosal and inhibition of DNA topoisomerase II alpha.

Wu X, Liang H, O'Hara KA, Yalowich JC, Hasinoff BB.

Chem Res Toxicol. 2008 Feb;21(2):483-93. doi: 10.1021/tx700341n. Epub 2008 Jan 16.

PMID:
18197631
26.

A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.

Liang H, Wu X, Yalowich JC, Hasinoff BB.

Mol Pharmacol. 2008 Mar;73(3):686-96. Epub 2007 Nov 28.

27.

Mechanism of the cytotoxicity of the diazoparaquinone antitumor antibiotic kinamycin F.

O'Hara KA, Wu X, Patel D, Liang H, Yalowich JC, Chen N, Goodfellow V, Adedayo O, Dmitrienko GI, Hasinoff BB.

Free Radic Biol Med. 2007 Oct 15;43(8):1132-44. Epub 2007 Jul 13.

28.

c-Abl kinase regulates curcumin-induced cell death through activation of c-Jun N-terminal kinase.

Kamath R, Jiang Z, Sun G, Yalowich JC, Baskaran R.

Mol Pharmacol. 2007 Jan;71(1):61-72. Epub 2006 Oct 4.

29.

Kinamycins A and C, bacterial metabolites that contain an unusual diazo group, as potential new anticancer agents: antiproliferative and cell cycle effects.

Hasinoff BB, Wu X, Yalowich JC, Goodfellow V, Laufer RS, Adedayo O, Dmitrienko GI.

Anticancer Drugs. 2006 Aug;17(7):825-37.

PMID:
16926632
30.

A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.

Liang H, Wu X, Guziec LJ, Guziec FS Jr, Larson KK, Lang J, Yalowich JC, Hasinoff BB.

J Chem Inf Model. 2006 Jul-Aug;46(4):1827-35.

PMID:
16859314
31.

Myeloperoxidase-catalyzed metabolism of etoposide to its quinone and glutathione adduct forms in HL60 cells.

Fan Y, Schreiber EM, Giorgianni A, Yalowich JC, Day BW.

Chem Res Toxicol. 2006 Jul;19(7):937-43. Erratum in: Chem Res Toxicol. 2007 Jul;20(7):1067.

PMID:
16841962
32.

Increased mutant frequencies in the HPRT gene locus of leukemia HL-60 cells treated with succinylacetone.

Zheng KC, Yalowich JC, Kagan VE, Keohavong P.

Cell Biol Toxicol. 2006 Sep;22(5):361-70. Epub 2006 Jul 11.

PMID:
16838078
33.

Mechanisms of cardiolipin oxidation by cytochrome c: relevance to pro- and antiapoptotic functions of etoposide.

Tyurina YY, Kini V, Tyurin VA, Vlasova II, Jiang J, Kapralov AA, Belikova NA, Yalowich JC, Kurnikov IV, Kagan VE.

Mol Pharmacol. 2006 Aug;70(2):706-17. Epub 2006 May 11.

34.

Structure-activity study of the interaction of bioreductive benzoquinone alkylating agents with DNA topoisomerase II.

Hasinoff BB, Wu X, Begleiter A, Guziec LJ, Guziec F Jr, Giorgianni A, Yang S, Jiang Y, Yalowich JC.

Cancer Chemother Pharmacol. 2006 Jan;57(2):221-33. Epub 2005 Jul 12.

PMID:
16010589
35.

Biochemical and proteomics approaches to characterize topoisomerase IIalpha cysteines and DNA as targets responsible for cisplatin-induced inhibition of topoisomerase IIalpha.

Hasinoff BB, Wu X, Krokhin OV, Ens W, Standing KG, Nitiss JL, Sivaram T, Giorgianni A, Yang S, Jiang Y, Yalowich JC.

Mol Pharmacol. 2005 Mar;67(3):937-47. Epub 2004 Dec 15.

36.

Lipid antioxidant, etoposide, inhibits phosphatidylserine externalization and macrophage clearance of apoptotic cells by preventing phosphatidylserine oxidation.

Tyurina YY, Serinkan FB, Tyurin VA, Kini V, Yalowich JC, Schroit AJ, Fadeel B, Kagan VE.

J Biol Chem. 2004 Feb 13;279(7):6056-64. Epub 2003 Nov 20.

37.

Direct evidence for recycling of myeloperoxidase-catalyzed phenoxyl radicals of a vitamin E homologue, 2,2,5,7,8-pentamethyl-6-hydroxy chromane, by ascorbate/dihydrolipoate in living HL-60 cells.

Kagan VE, Kuzmenko AI, Shvedova AA, Kisin ER, Li R, Martin I, Quinn PJ, Tyurin VA, Tyurina YY, Yalowich JC.

Biochim Biophys Acta. 2003 Mar 17;1620(1-3):72-84.

PMID:
12595076
38.
39.

Anti-/pro-oxidant effects of phenolic compounds in cells: are colchicine metabolites chain-breaking antioxidants?

Modriansky M, Tyurina YY, Tyurin VA, Matsura T, Shvedova AA, Yalowich JC, Kagan VE.

Toxicology. 2002 Aug 1;177(1):105-17.

PMID:
12126799
40.

Pro-oxidant and antioxidant mechanisms of etoposide in HL-60 cells: role of myeloperoxidase.

Kagan VE, Kuzmenko AI, Tyurina YY, Shvedova AA, Matsura T, Yalowich JC.

Cancer Res. 2001 Nov 1;61(21):7777-84.

41.

Synthesis and biological activity of a photoaffinity etoposide probe.

Hasinoff BB, Chee GL, Day BW, Avor KS, Barnabé N, Thampatty P, Yalowich JC.

Bioorg Med Chem. 2001 Jul;9(7):1765-71.

PMID:
11425578
42.

Antioxidant mechanisms of nitric oxide against iron-catalyzed oxidative stress in cells.

Kagan VE, Kozlov AV, Tyurina YY, Shvedova AA, Yalowich JC.

Antioxid Redox Signal. 2001 Apr;3(2):189-202. Review.

PMID:
11396475
43.

The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.

Hasinoff BB, Abram ME, Barnabé N, Khélifa T, Allan WP, Yalowich JC.

Mol Pharmacol. 2001 Mar;59(3):453-61.

44.

The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.

Hasinoff BB, Abram ME, Chee GL, Huebner E, Byard EH, Barnabé N, Ferrans VJ, Yu ZX, Yalowich JC.

J Pharmacol Exp Ther. 2000 Nov;295(2):474-83.

45.

Myeloperoxidase-catalyzed phenoxyl radicals of vitamin E homologue, 2,2,5,7,8-pentamethyl- 6-hydroxychromane, do not induce oxidative stress in live HL-60 cells.

Kagan VE, Kuzmenko AI, Shvedova AA, Kisin ER, Tyurina YY, Yalowich JC.

Biochem Biophys Res Commun. 2000 Apr 21;270(3):1086-92.

PMID:
10772954
46.

Mechanism-based chemopreventive strategies against etoposide-induced acute myeloid leukemia: free radical/antioxidant approach.

Kagan VE, Yalowich JC, Borisenko GG, Tyurina YY, Tyurin VA, Thampatty P, Fabisiak JP.

Mol Pharmacol. 1999 Sep;56(3):494-506.

47.

Mechanisms of nitric oxide protection against tert-butyl hydroperoxide-induced cytotoxicity in iNOS-transduced human erythroleukemia cells.

Yalowich JC, Gorbunov NV, Kozlov AV, Allan W, Kagan VE.

Biochemistry. 1999 Aug 17;38(33):10691-8.

PMID:
10451363
49.

Induction of human breast cancer cell apoptosis from G2/M preceded by stimulation into the cell cycle by Z-1,1-dichloro-2,3-diphenylcyclopropane.

Balachandran R, ter Haar E, Yalowich JC, Welsh MJ, Grant SG, Day BW.

Biochem Pharmacol. 1999 Jan 1;57(1):97-110.

PMID:
9920290

Supplemental Content

Loading ...
Support Center